Allogene Therapeutics Inc. (ALLO)
Market Closed
16 Oct, 08:00 PM
NASDAQ (NGS) NASDAQ (NGS) Primary $
1. 31
-0.03
-2.2388%
$
503.93M Market Cap
- P/E Ratio
- Div Yield
4.92M Volume
-2.03 Eps
$ 1.34
Previous Close 
Want to track ALLO and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Allogene (ALLO) Posts Narrower Than Expected Loss in Q2
Allogene's (ALLO) second-quarter earnings beat estimates but sales miss the mark. It expects to submit a regulatory filing with the FDA for its lead pipeline drug in large B-cell lymphoma indication by 2027.
Zacks | 2 years ago
7 Biotech Stocks to Buy for Their Game-Changing Potential
With the market struggling amid rising recession fears, now may be the ideal time to consider biotech stocks. First, the sector itself is a financially lucrative one.
Investorplace | 2 years ago
If You Can Only Buy One Penny Stock in May, It Better Be One of These 3 Names
Penny stocks carry a great deal of risk. It's why investors are often told to steer clear of them.
Investorplace | 2 years ago
2026 © Marketlog. All Rights Reserved.
